---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-227053"
form_type: "8-K"
ticker: "WVE"
cik: "0001631574"
company_name: "Wave Life Sciences Ltd."
filed_at: "2024-09-26T23:59:59+00:00"
generated_at: "2026-05-31T01:33:56.410740+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Wave Life Sciences prices upsized $200M public offering of ordinary shares and pre-funded warrants

## Summary
- Offering of 23.1M ordinary shares at $8.00/share and 1.9M pre-funded warrants at $7.9999 each; gross proceeds ~$200M.
- Underwriters have 30-day option to purchase up to an additional 3.75M ordinary shares on same terms.
- Offering expected to close on or about Sept 27, 2024; cash runway extended into 2027 excluding GSK/Takeda milestones.
- Following close, pro forma ordinary shares outstanding expected to be approximately 148.4M.
- J.P. Morgan and Leerink Partners acting as joint book-running managers; Truist and Mizuho as book-runners.

## SEC filing metadata
- accession: 0001193125-24-227053
- form_type: 8-K
- ticker: WVE
- cik: 0001631574
- company_name: Wave Life Sciences Ltd.
- filed_at: 2024-09-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1631574/000119312524227053/0001193125-24-227053-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1631574/000119312524227053/d817468d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-227053
- JSON: https://secwatch.observer/filing/0001193125-24-227053.json
- Plain text: https://secwatch.observer/filing/0001193125-24-227053.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.